LONDON (Reuters) - GlaxoSmithKline chief executive said on Wednesday she had no interest in acquiring Shire, the London-listed rare diseases specialist that Takeda Pharmaceutical hopes to buy for some $64 billion (46 billion pounds).

Emma Walmsley, speaking to reporters after first-quarter results, said the British drugmaker's focus was on deals to acquire early-stage experimental drugs that would help rebuild the company's pharmaceuticals pipeline.

(Reporting by Ben Hirschler; editing by Jason Neely)